

Subject Index

- acyclovir 83
- ADCC (see antibody-dependent cellular cytotoxicity)
- adeno-associated virus (AAV) 165
- adjuvants 144
- agammaglobulinemia 42, 81
- age of animal 92
- α genes 4
- α -proteins (see immediate early proteins)
- α -TIF 4, 9, 10
- animal models 57, 61
 - of PNS infection 33–35
 - – desired characteristics 33
 - – zosteriform spread 34
- animals
 - cebus monkeys 21
 - guinea pig 17, 19–23
 - hamsters 21
 - marmosets 21
 - mouse 17–19, 23, 24
 - owl monkeys 21
 - rabbit 18, 20
 - rat 24
 - tree shrew 24
- antibody, antibodies 75
 - agammaglobulinemia 42
 - B cell suppression 41, 42
 - bipolar bridging 117, 118
 - Fc receptor 77
 - mechanisms of action in PNS 42, 43
 - passive transfer experiments 40, 41
 - role of establishment of latency 43, 44
 - role in primary infection of PNS 40–43
- antibody-dependent cellular cytotoxicity (ADCC) 76, 77, 79
 - role of HSV Fc receptor in protection from 117, 118
- antisense
 - complementary to HSV-1
 - – ICP4 168
 - – ICP22 166
 - – ICP47 166
 - oligonucleotides 166
 - RNA 161, 168
- antiviral 159
 - resistance mechanisms, MO-mediated 94
- B cell suppression 41, 42
- back door hypothesis 43
- BCRF1 111
- β_2 -microglobulin 111
- β -genes 6
 - expression 6
 - function 6
 - promoter 6
- β -proteins 6
- bone marrow transplant patients 83
- C3 receptor, encoded by HSV
 - interaction with complement 114
 - neuraminidase treatment 113
 - mutational analysis 113, 114
- capsaicin 25, 26
- capsid protein, major 8
- capsular cells, ganglionic 32
- CD11 deficiency 77
- CD18 deficiency 77
- CD4 59, 60, 63, 65–69
- CD4+ 122, 123, 129
 - subsets 125
- CD8 (see also T cells) 46, 60, 61, 63, 65–69
- CD8+ 128
- cebus monkeys 21

- clinical disease
 - disseminated 17
 - encephalitis 17, 20, 21
 - genital 17, 21, 22
 - humans 16
 - neonatal 17, 20, 21
 - ocular 18, 19
 - orolabial 17
- Cmv-1 40
- complement
 - components
 - - C1q 117, 118
 - - C3 fragments 112-115, 118
 - receptor type I 112
- cytokines 57, 61, 62, 95, 104
- cytotoxic T lymphocyte (CTL) 58-69
- cytotoxicity 92

- dermatome 32
- disseminated disease 80
- DNA
 - binding protein, ICP8 7
 - polymerase, viral 7
 - replication 2
 - synthesis 3
- dorsal root ganglion 32
- draining lymph node cells 45

- early genes (E) 2
 - β 1 2
 - β 2 2
 - DNA
 - - binding protein 7
 - - polymerase 7
 - - synthesis 6
 - helicase 7
 - nucleotid metabolism 8
 - origin binding protein 7
 - primase 7
 - promoters 6
- early polypeptides (see early genes)
- ELISA (see enzyme-linked immune absorption)
- encephalitis 17, 20, 21, 80
- envelope of the virus 9
- enzyme-linked immune absorption (ELISA) 75, 79

- Fc receptor
 - encoded by HSV
 - - binding of IgG-coated erythrocytes 116
 - - binding of monomeric IgG 116
 - - effects of temperature on IgG binding 115
 - - formation by interaction of gE and gI 116
 - - kinetics of expression 115
 - - role in inhibition of viral replication 117
 - - role in protection from
 - - - antibody 117
 - - - antibody dependent cellular cytotoxicity (ADCC) 117, 118
 - - - complement-mediated neutralization 117
 - mammalian 116-117
- glycoproteins 8
 - envelope 9, 10
 - gB 9, 77, 83
 - gC 8, 9, 76, 83
 - - role in HSV C3 receptor formation 112-115
 - gD 9, 77, 83
 - gE 9, 76, 83
 - - role in HSV Fc receptor formation 116
 - gG 9
 - gH 9
 - gI 9
 - gJ 9
- gene therapy 159
- genital disease 17, 21, 22
- guinea pig 17, 19-23

- hamsters 21
- helicase 7
- heparin sulfate 9
- Herpesviridae 1
- herpetic stromal keratitis (HSK) 126, 127
- HIV 161-163
- HSK (see herpetic stromal keratitis)
- HSV (herpes simplex virus)
 - antibodies, transplacental 79
 - infection
 - - genetic resistance to 38-40
 - - - MHC-linked 38
 - - - non-MHC-linked 39
 - - natural resistance 90, 169
 - - passive protection 76
 - latency 10
- HSV-1
 - glycoprotein D 167
 - ICP4
 - - antisense RNA targeted to 168
 - - transdominant mutant of 169

- ICP22 166
- ICP47 166
- VP16 (Vmw65) 167, 168
- HSV-2 168
 - gG 80
- human
 - clinical trials 145–153
 - – killed whole virus vaccines 145, 146
 - – nonspecific immune enhancers 145
 - – open 145–153
 - – placebo controlled 145, 146, 148–151, 153
 - – purified fractions of virus 146–151
 - – subunit 152, 153
 - neonates 78
 - studies 57, 58, 69
- ICP8 7
- IE (see immediate early proteins)
- I β -1 40
- IFN (see interferon)
- immediate early proteins (IE, α proteins) 2
 - α 0 4, 5
 - α 4 4
 - α 22 4, 6, 9
 - α 27 4, 5, 9
 - α 47 4, 6
 - trans-activator 5
 - transpressor 5
 - zinc-finger 5
- immune complex disease 122
- immune evasion by
 - cytomegalovirus 111, 112
 - Epstein-Barr virus 111, 112
 - HSV 111–120
 - varicella zoster virus 112
- immune globulin 81
- immunity, cell mediated 58, 67, 69
 - cytotoxic T lymphocyte (CTL) 58–69
 - CD4 59, 60, 63, 65–69
 - CD8 60, 61, 63, 65–69
- immunocompromised patients 83
- immunocompromised host 77
- immunodeficiency
 - common variable 82
 - syndrome 81
- immunologic response 23
- immunopathology
 - in herpetic infections 125
 - – herpetic stromal keratitis (HSK) 126, 127
 - – role of CD8⁺ 128
 - – uveitis 126
- mechanisms 122
 - – delayed type hypersensitivity (DTH) reaction 124, 130
 - – immune complex disease 122
 - – direct T cell cytotoxicity 130
- immunosurgery 46
 - CD8 selective 46
 - effect on virus clearance 46–48
- immunotherapy 23
- infection, latent 10
- interferon (IFN) 95, 96, 100, 164
 - α , genetic control 40
- interleukin 10 111
- intracellular immunization 159
 - antibody binding domains 164
 - interferon 164
 - ribozymes 162
 - RNA
 - – antisense 161, 168
 - – sense 162
 - transdominant mutant proteins 163, 168, 169
 - viral receptor analogs 163
- intranuclear transport 19
- killed virus vaccines 142–153
 - purified fractions of virus 142–143, 145–151
 - subunit 142–144, 152, 153
 - – chimeric particle 145
 - – glycoprotein 143, 144, 152, 153
 - – peptide 144, 145
 - – recombinant 143, 144, 152, 153
- L (see late genes)
- Langerhans' cells 103
- late genes (L, γ) 2
 - fibroblast growth factor 10
 - γ 1 8
 - γ 2 8
 - heparin sulfate 9
 - promoter sequences 8
 - transcriptional control 9
 - virus particle 9
- latency 16, 19–21, 25, 36, 37
 - associated transcript (LAT) 11
- latent infection 10
- leukemia 82
- lipid membrane 1

- live virus vaccines 139–142
 - attenuated HSV 140, 141
 - recombinant
 - – adenovirus vectors 141, 142
 - – vaccinia virus vectors 141
- lymphocytes 77
- macrophage (MO) 77, 90
 - activation 97
 - cell lines 99
 - differentiation 97
 - maturation 97
 - mouse resistant peritoneal 94
- major histocompatibility complex (MHC)
 - diversity 39
 - immunoregulatory functions 38
 - influence on PNS infection 38, 39
 - restriction 38
- marmosets 21
- microglobulin (see β_2 -microglobulin)
- MO-cell lines 99
- monensin 25
- monoclonal antibodies 76, 77
- monocyte-MO cell lines 99
- monocytes, human 95
- mouse 17–19, 23, 24
 - resistant peritoneal MOs 94
- Mx-1 164
- natural killer (NK) cells 82, 102
- natural resistance 90
- neonatal
 - disease 17, 20, 21
 - herpes 78
 - HSV 79
- neonates 77
 - human 78
- neural virulence 19, 20
- neurodermatome 32
- neutralization 76, 79
- nonspecific defense 89–107
- nucleocapsid 1
- ocular disease 18, 19
- orolabial disease 17
- owl monkeys 21
- p45 83
- passive
 - immunization 77
 - protection 76
- pathogenesis 17, 24–26
- patients, immunocomprised 83
- peripheral nervous system (PNS)
 - anatomy 32
 - infection 31–51
 - – immune control 38–51
 - interaction with HSV 36–37
- phagocytic function 93
- PMN 101
- primary infection, mother 78
- primary sensory neurons 32
 - fetal, cultured 36
- primase 7
- promoter sequences 8
- prophylaxis 138–143, 146, 150, 151
- protein A of *Staphylococcus Aureus* 116, 117
- rabbit 18, 20
- radiation, ultraviolet 22, 26
- radioimmunoassay 75
- rat 24
- reactivation 16, 26, 37
 - immune control 51
- recrudescence
 - immune control 51
 - – IFN- γ levels 51
 - – lymphocyte proliferation 51
 - – suppressor T cells 51
 - influence of HLA type 38
- recurrent infection 78
- regulatory cascade 2
- renal transplants 82
- replication protein 7
 - U_L5 7
 - U_L8 7
 - U_L9 7
 - U_L29 7
 - U_L30 7
 - U_L52 7
- retrovirus vectors 165
- ribonucleotide reductase 8, 167
- ribozymes 162
- RNA
 - antisense 161, 168
 - polymerase II 3
 - sense 162
- round trip hypothesis 43
- T cell
 - adoptive transfer 45, 46
 - CD8⁺ 38, 45, 122
 - – mechanisms of action in PNS 49
 - – selective depletion in vivo 46–48
 - – stimulation on PNS 49
 - cytotoxic 44, 45, 49

- cytotoxicity 130
- mediated immunopathology 122, 128
- - CD4+ subsets 125
- - CD4+ T cell mediated 123, 129
- - CD8+ T cell mediated 122
- T lymphocyte, cytotoxic (CTL) 58-69
- tegument 1, 10
- therapy 138, 139, 144, 145, 147-149, 151, 153
- thymidine kinase 8
- transdominant mutant proteins 163, 168, 169
- transplacental
 - antibody 78
 - HSV antibodies 79
- tree shrew 24

- ultraviolet radiation 22, 26
- uveitis 126

- vectors, eukaryotic 165
- viral
 - genome 11
 - receptors 163
- virion 1, 2
 - glycoproteins 1
 - host switchoff protein (vhs) 10
 - lipid membrane 1
 - nucleocapsid 1
 - tegument 1
- virulence, neural 19, 20
- virus replication, inhibition 93
- Vp16 83
- Vp66 83

- western blot 75, 79

- X-linked (Bruton's) agammaglobulinemia 81

- zosteriform 23
 - lesion 34

Current Topics in Microbiology and Immunology

Volumes published since 1987 (and still available)

Vol. 135: **Paige, Christopher J.; Gisler, Roland H. (Ed.):** Differentiation of B Lymphocytes. 1987. 25 figs. IX, 150 pp. ISBN 3-540-17470-2

Vol. 136: **Hobom, Gerd; Rott, Rudolf (Ed.):** The Molecular Biology of Bacterial Virus Systems. 1988. 20 figs. VII, 90 pp. ISBN 3-540-18513-5

Vol. 137: **Mock, Beverly; Potter, Michael (Ed.):** Genetics of Immunological Diseases. 1988. 88 figs. XI, 335 pp. ISBN 3-540-19253-0

Vol. 138: **Goebel, Werner (Ed.):** Intracellular Bacteria. 1988. 18 figs. IX, 179 pp. ISBN 3-540-50001-4

Vol. 139: **Clarke, Adrienne E.; Wilson, Ian A. (Ed.):** Carbohydrate-Protein Interaction. 1988. 35 figs. IX, 152 pp. ISBN 3-540-19378-2

Vol. 140: **Podack, Eckhard R. (Ed.):** Cytotoxic Effector Mechanisms. 1989. 24 figs. VIII, 126 pp. ISBN 3-540-50057-X

Vol. 141: **Potter, Michael; Melchers, Fritz (Ed.):** Mechanisms in B-Cell Neoplasia 1988. Workshop at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, March 23–25, 1988. 122 figs. XIV, 340 pp. ISBN 3-540-50212-2

Vol. 142: **Schüpach, Jörg:** Human Retrovirology. Facts and Concepts. 1989. 24 figs. 115 pp. ISBN 3-540-50455-9

Vol. 143: **Haase, Ashley T.; Oldstone Michael B. A. (Ed.):** In Situ Hybridization 1989. 22 figs. XII, 90 pp. ISBN 3-540-50761-2

Vol. 144: **Knippers, Rolf; Levine, A. J. (Ed.):** Transforming. Proteins of DNA Tumor Viruses. 1989. 85 figs. XIV, 300 pp. ISBN 3-540-50909-7

Vol. 145: **Oldstone, Michael B. A. (Ed.):** Molecular Mimicry. Cross-Reactivity between Microbes and Host Proteins as a Cause of Autoimmunity. 1989. 28 figs. VII, 141 pp. ISBN 3-540-50929-1

Vol. 146: **Mestecky, Jiri; McGhee, Jerry (Ed.):** New Strategies for Oral Immunization. International Symposium at the University of Alabama at Birmingham and Molecular Engineering Associates, Inc. Birmingham, AL, USA, March 21–22, 1988. 1989. 22 figs. IX, 237 pp. ISBN 3-540-50841-4

Vol. 147: **Vogt, Peter K. (Ed.):** Oncogenes. Selected Reviews. 1989. 8 figs. VII, 172 pp. ISBN 3-540-51050-8

Vol. 148: **Vogt, Peter K. (Ed.):** Oncogenes and Retroviruses. Selected Reviews. 1989. XII, 134 pp. ISBN 3-540-51051-6

Vol. 149: **Shen-Ong, Grace L. C.; Potter, Michael; Copeland, Neal G. (Ed.):** Mechanisms in Myeloid Tumorigenesis. Workshop at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA, March 22, 1988. 1989. 42 figs. X, 172 pp. ISBN 3-540-50968-2

Vol. 150: **Jann, Klaus; Jann, Barbara (Ed.):** Bacterial Capsules. 1989. 33 figs. XII, 176 pp. ISBN 3-540-51049-4

Vol. 151: **Jann, Klaus; Jann, Barbara (Ed.):** Bacterial Adhesins. 1990. 23 figs. XII, 192 pp. ISBN 3-540-51052-4

Vol. 152: **Bosma, Melvin J.; Phillips, Robert A.; Schuler, Walter (Ed.):** The Scid Mouse. Characterization and Potential Uses. EMBO Workshop held at the Basel Institute for Immunology, Basel, Switzerland, February 20–22, 1989. 1989. 72 figs. XII, 263 pp. ISBN 3-540-51512-7

Vol. 153: **Lambris, John D. (Ed.):** The Third Component of Complement. Chemistry and Biology. 1989. 38 figs. X, 251 pp. ISBN 3-540-51513-5

Vol. 154: **McDougall, James K. (Ed.):** Cytomegaloviruses. 1990. 58 figs. IX, 286 pp. ISBN 3-540-51514-3

Vol. 155: **Kaufmann, Stefan H. E. (Ed.):** T-Cell Paradigms in Parasitic and Bacterial Infections. 1990. 24 figs. IX, 162 pp. ISBN 3-540-51515-1

Vol. 156: **Dyrberg, Thomas (Ed.):** The Role of Viruses and the Immune System in Diabetes Mellitus. 1990. 15 figs. XI, 142 pp. ISBN 3-540-51918-1

Vol. 157: **Swanstrom, Ronald; Vogt, Peter K. (Ed.):** Retroviruses. Strategies of Replication. 1990. 40 figs. XII, 260 pp. ISBN 3-540-51895-9

Vol. 158: **Muzyczka, Nicholas (Ed.):** Viral Expression Vectors. 1992. 20 figs. IX, 176 pp. ISBN 3-540-52431-2

Vol. 159: **Gray, David; Sprent, Jonathan (Ed.):** Immunological Memory. 1990. 38 figs. XII, 156 pp. ISBN 3-540-51921-1

Vol. 160: **Oldstone, Michael B. A.; Koprowski, Hilary (Ed.):** Retrovirus Infections of the Nervous System. 1990. 16 figs. XII, 176 pp. ISBN 3-540-51939-4

Vol. 161: **Racaniello, Vincent R. (Ed.):** Picornaviruses. 1990. 12 figs. X, 194 pp. ISBN 3-540-52429-0

Vol. 162: **Roy, Polly; Gorman, Barry M. (Ed.):** Bluetongue Viruses. 1990. 37 figs. X, 200 pp. ISBN 3-540-51922-X

Vol. 163: **Turner, Peter C.; Moyer, Richard W. (Ed.):** Poxviruses. 1990. 23 figs. X, 210 pp. ISBN 3-540-52430-4

Vol. 164: **Bækkeskov, Steinnun; Hansen, Bruno (Ed.):** Human Diabetes. 1990. 9 figs. X, 198 pp. ISBN 3-540-52652-8

Vol. 165: **Bothwell, Mark (Ed.):** Neuronal Growth Factors. 1991. 14 figs. IX, 173 pp. ISBN 3-540-52654-4

Vol. 166: **Potter, Michael; Melchers, Fritz (Ed.):** Mechanisms in B-Cell Neoplasia 1990. 143 figs. XIX, 380 pp. ISBN 3-540-52886-5

Vol. 167: **Kaufmann, Stefan H. E. (Ed.):** Heat Shock Proteins and Immune Response. 1991. 18 figs. IX, 214 pp. ISBN 3-540-52857-1

Vol. 168: **Mason, William S.; Seeger, Christoph (Ed.):** Hepadnaviruses. Molecular Biology and Pathogenesis. 1991. 21 figs. X, 206 pp. ISBN 3-540-53060-6

Vol. 169: **Kolakofsky, Daniel (Ed.):** Bunyaviridae. 1991. 34 figs. X, 256 pp. ISBN 3-540-53061-4

Vol. 170: **Compans, Richard W. (Ed.):** Protein Traffic in Eukaryotic Cells. Selected Reviews. 1991. 14 figs. X, 186 pp. ISBN 3-540-53631-0

Vol. 171: **Kung, Hsing-Jien; Vogt, Peter K. (Eds.):** Retroviral Insertion and Oncogene Activation. 1991. 18 figs. X, 179 pp. ISBN 3-540-53857-7

Vol. 172: **Chesebro, Bruce W. (Ed.):** Transmissible Spongiform Encephalopathies. 1991. 48 figs. X, 288 pp. ISBN 3-540-53883-6

Vol. 173: **Pfeffer, Klaus; Heeg, Klaus; Wagner, Hermann; Riethmüller, Gert (Ed.):** Function and Specificity of γ/δ T Cells. 1991. 41 figs. XII, 296 pp. ISBN 3-540-53781-3

Vol. 174: **Fleischer, Bernhard; Sjögren, Hans Olov (Eds.):** Superantigens. 1991. 13 figs. IX, 137 pp. ISBN 3-540-54205-1

Vol. 175: **Aktories, Klaus (Ed.):** ADP-Ribosylating Toxins. 1992. 23 figs. IX, 148 pp. ISBN 3-540-54598-0

Vol. 176: **Holland, John J. (Ed.):** Genetic Diversity of RNA Viruses. 1992. 34 figs. IX, 226 pp. ISBN 3-540-54652-9

Vol. 177: **Müller-Sieburg, Christa; Torok-Storb, Beverly; Visser, Jan; Storb, Rainer (Eds.):** Hematopoietic Stem Cells. 1992. 18 figs. XIII, 143 pp. ISBN 3-540-54531-X

Vol. 178: **Parker, Charles J. (Ed.):** Membrane Defenses Against Attack by Complement and Perforins. 1992. 26 figs. VIII, 188 pp. ISBN 3-540-54653-7